OKUR has 36-month beta value of 0.31. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OKUR is 2.44M, and currently, short sellers hold a 45.98% ratio of that float. The average trading volume of OKUR on December 20, 2024 was 73.82K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
OKUR) stock’s latest price update
The stock price of OnKure Therapeutics Inc (NASDAQ: OKUR) has dropped by -6.50 compared to previous close of 8.61. Despite this, the company has seen a fall of -25.67% in its stock price over the last five trading days. globenewswire.com reported 2024-12-10 that — OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported
OKUR’s Market Performance
OnKure Therapeutics Inc (OKUR) has seen a -25.67% fall in stock performance for the week, with a -50.88% decline in the past month and a -46.33% plunge in the past quarter. The volatility ratio for the week is 12.04%, and the volatility levels for the past 30 days are at 9.12% for OKUR. The simple moving average for the past 20 days is -38.21% for OKUR’s stock, with a -49.52% simple moving average for the past 200 days.
Analysts’ Opinion of OKUR
Many brokerage firms have already submitted their reports for OKUR stocks, with Leerink Partners repeating the rating for OKUR by listing it as a “Outperform.” The predicted price for OKUR in the upcoming period, according to Leerink Partners is $33 based on the research report published on December 05, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see OKUR reach a price target of $35. The rating they have provided for OKUR stocks is “Outperform” according to the report published on October 10th, 2024.
OKUR Trading at -48.78% from the 50-Day Moving Average
After a stumble in the market that brought OKUR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.75% of loss for the given period.
Volatility was left at 9.12%, however, over the last 30 days, the volatility rate increased by 12.04%, as shares sank -49.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -56.49% lower at present.
During the last 5 trading sessions, OKUR fell by -25.67%, which changed the moving average for the period of 200-days by -50.31% in comparison to the 20-day moving average, which settled at $13.03. In addition, OnKure Therapeutics Inc saw -49.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OKUR starting from Leonard Braden Michael, who purchase 68,746 shares at the price of $1.50 back on Sep 25 ’24. After this action, Leonard Braden Michael now owns 3,457,395 shares of OnKure Therapeutics Inc, valued at $102,872 using the latest closing price.
Leonard Braden Michael, the 10% Owner of OnKure Therapeutics Inc, purchase 29,600 shares at $1.41 during a trade that took place back on Sep 24 ’24, which means that Leonard Braden Michael is holding 3,388,649 shares at $41,866 based on the most recent closing price.
Stock Fundamentals for OKUR
Equity return is now at value -54.00, with -49.87 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 57.86.
Conclusion
To put it simply, OnKure Therapeutics Inc (OKUR) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
